David R. Beers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David R. Beers has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Aaron D. Thome
Department of Neurology, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX 77030, USA
3 shared publications - Alireza Faridar
Stanley H. Appel Department of Neurology, Houston Methodist Research Institute, Houston, USA
3 shared publications - Joseph C. Masdeu
Nantz National Alzheimer Center, Houston Methodist Neurological Institute and Weill Cornell Medicine, Houston, TX 77030, USA
3 shared publications - Stanley H. Appel
Department of Neurology, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Houston Methodist Hospital, United States
3 shared publications - Weihua Zhao
Department of Neurology, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX 77030, USA
3 shared publications - Belen Pascual
Department of Neurology, Houston Methodist, Houston, USA
2 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7855
Combination GLP-1RA and Low-Dose IL-2 Modulates Peripheral Immune Activation and Attenuates CNS Inflammatory Transcript Signatures In Vivo
Immune dysregulation characterized by persistent myeloid activation and associated impairment of regulatory T cell (Treg) function contributes to inflammatory signaling across peripheral and central compartments in neurodegenerative diseases. We evaluated whether combining a glucagon-like peptide-1 receptor agonist (GLP-1RA; semaglutide) with low-dose interleukin-2 (LD-IL2) could modulate myeloid-associated transcript expression and enhance Treg-associated regulatory transcripts in a subacute lipopolysaccharide (LPS)-induced model of systemic and CNS inflammation. Mice received LPS once daily for 5 days, while GLP-1RA, LD-IL2, or combination treatment was initiated 24 h after LPS onset and continued daily. Splenic immune populations were quantified, and transcript expressions were assessed in magnetically enriched CD11b+ myeloid cells and CD4+CD25+ Tregs, as well as in cortex and hippocampus. As monotherapies, GLP-1RA reduced myeloid expansion with modest modulation of pro-inflammatory and anti-inflammatory myeloid transcripts, whereas LD-IL2 selectively enhanced Treg numbers and increased transcripts associated with Treg stability and suppressive regulation, including Il2ra (CD25), Foxp3, Ctla4, Ikzf2 (HELIOS), Entpd1 (CD39), and Nt5e (CD73). Combination treatment significantly reduced LPS-induced myeloid Il6, Il1b, and Tnf expression and increased Arg1 expression. Combination treatment further enhanced Treg-associated Il2ra (CD25), Tgfb1, and Ctla4 expression relative to monotherapies. In cortical and hippocampal tissues, combination treatment produced more robust modulation of inflammatory transcripts compared with effects observed with monotherapies, including reductions in Il6 and Il1b and increases in Cd163 and Mrc1 (CD206) expression. Together, these findings demonstrate coordinated and complementary changes in peripheral immune-cell populations and myeloid inflammatory and Treg-associated regulatory transcripts and warrant further evaluation of this combination in inflammation-driven neurodegenerative disease.
- 2 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7855
Open AccessCombination GLP-1RA and Low-Dose IL-2 Modulates Peripheral Immune Activation and Attenuates CNS Inflammatory Transcript Signatures In Vivo
Immune dysregulation characterized by persistent myeloid activation and associated impairment of regulatory T cell (Treg) function contributes to inflammatory signaling across peripheral and central compartments in neurodegenerative diseases. We evaluated whether combining a glucagon-like peptide-1 receptor agonist (GLP-1RA; semaglutide) with low-dose interleukin-2 (LD-IL2) could modulate myeloid-associated transcript expression and enhance Treg-associated regulatory transcripts in a subacute lipopolysaccharide (LPS)-induced model of systemic and CNS inflammation. Mice received LPS once daily for 5 days, while GLP-1RA, LD-IL2, or combination treatment was initiated 24 h after LPS onset and continued daily. Splenic immune populations were quantified, and transcript expressions were assessed in magnetically enriched CD11b+ myeloid cells and CD4+CD25+ Tregs, as well as in cortex and hippocampus. As monotherapies, GLP-1RA reduced myeloid expansion with modest modulation of pro-inflammatory and anti-inflammatory myeloid transcripts, whereas LD-IL2 selectively enhanced Treg numbers and increased transcripts associated with Treg stability and suppressive regulation, including Il2ra (CD25), Foxp3, Ctla4, Ikzf2 (HELIOS), Entpd1 (CD39), and Nt5e (CD73). Combination treatment significantly reduced LPS-induced myeloid Il6, Il1b, and Tnf expression and increased Arg1 expression. Combination treatment further enhanced Treg-associated Il2ra (CD25), Tgfb1, and Ctla4 expression relative to monotherapies. In cortical and hippocampal tissues, combination treatment produced more robust modulation of inflammatory transcripts compared with effects observed with monotherapies, including reductions in Il6 and Il1b and increases in Cd163 and Mrc1 (CD206) expression. Together, these findings demonstrate coordinated and complementary changes in peripheral immune-cell populations and myeloid inflammatory and Treg-associated regulatory transcripts and warrant further evaluation of this combination in inflammation-driven neurodegenerative disease.
- 30 July 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (1) , 505-517
Translocator protein (TSPO) positron emission tomography imaging and expression in patients with brain metastases
Purpose 18 kDa translocator protein (TSPO) is a biomarker for inflammatory conditions. However, full kinetic positron emission tomography (PET) modeling has rarely been used to quantify brain tumors, and it has never been used in brain metastases (BMs). This proof-of-principle study quantified TSPO expression using full kinetic modeling in patients with BMs from various types of peripheral primary tumors. Methods Nine adult patients with BMs and 12 healthy volunteers (HVs) took part in the study. The total distribution volume (VT) of 11C-ER176 was calculated with a two-tissue compartment model (2TCM) and metabolite-corrected arterial input function in the BMs and in the rest of the brain. Immunohistochemistry (IHC) and single-cell RNAseq database were used to quantify TSPO expression in vitro. The VT values of the hemisphere contralateral to the BMs were compared to the cortical values of HVs. Results 11C-ER176 uptake was increased in BMs compared with the rest of the brain of each participant. The BM time-activity curves were well-fitted by the 2TCM, and the resulting VT (range 3.2–13 mL/cm3) was identified with precision (standard error generally < 5%). The rate constant mostly affected by the integrity of the blood–brain barrier (BBB) (K1) was similar between the BMs and the contralateral hemisphere. TSPO expression was detected by IHC in tumor regions and variably in microglia/macrophages, a finding largely corroborated by single-cell RNAseq database. The average VT of the rest of the brain in BM patients was significantly lower than in HVs, which may have been due to immunosuppressive therapy. Conclusion In this pilot study, full kinetic modeling quantified TSPO expression in BMs with good fit and precision. The kinetic modeling outcome parameters and the TSPO expression levels in vitro suggest that 11C-ER176 binding was largely specific and not significantly affected by disruption of the BBB.
- 30 July 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (1) , 505-517
Translocator protein (TSPO) positron emission tomography imaging and expression in patients with brain metastases
Purpose 18 kDa translocator protein (TSPO) is a biomarker for inflammatory conditions. However, full kinetic positron emission tomography (PET) modeling has rarely been used to quantify brain tumors, and it has never been used in brain metastases (BMs). This proof-of-principle study quantified TSPO expression using full kinetic modeling in patients with BMs from various types of peripheral primary tumors. Methods Nine adult patients with BMs and 12 healthy volunteers (HVs) took part in the study. The total distribution volume (VT) of 11C-ER176 was calculated with a two-tissue compartment model (2TCM) and metabolite-corrected arterial input function in the BMs and in the rest of the brain. Immunohistochemistry (IHC) and single-cell RNAseq database were used to quantify TSPO expression in vitro. The VT values of the hemisphere contralateral to the BMs were compared to the cortical values of HVs. Results 11C-ER176 uptake was increased in BMs compared with the rest of the brain of each participant. The BM time-activity curves were well-fitted by the 2TCM, and the resulting VT (range 3.2–13 mL/cm3) was identified with precision (standard error generally < 5%). The rate constant mostly affected by the integrity of the blood–brain barrier (BBB) (K1) was similar between the BMs and the contralateral hemisphere. TSPO expression was detected by IHC in tumor regions and variably in microglia/macrophages, a finding largely corroborated by single-cell RNAseq database. The average VT of the rest of the brain in BM patients was significantly lower than in HVs, which may have been due to immunosuppressive therapy. Conclusion In this pilot study, full kinetic modeling quantified TSPO expression in BMs with good fit and precision. The kinetic modeling outcome parameters and the TSPO expression levels in vitro suggest that 11C-ER176 binding was largely specific and not significantly affected by disruption of the BBB.
- Open Access
- 30 September 2022
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 10 (1) , 1-13
Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer’s disease
Background: Regulatory T cells (Tregs) play a neuroprotective role by suppressing microglia and macrophage-mediated inflammation and modulating adaptive immune reactions. We previously documented that Treg immunomodulatory mechanisms are compromised in Alzheimer’s disease (AD). Ex vivo expansion of Tregs restores and amplifies their immunosuppressive functions in vitro. A key question is whether adoptive transfer of ex vivo expanded human Tregs can suppress neuroinflammation and amyloid pathology in a preclinical mouse model.Methods: An immunodeficient mouse model of AD was generated by backcrossing the 5xFAD onto Rag2 knockout mice (5xFAD-Rag2KO). Human Tregs were expanded ex vivo for 24 days and administered to 5xFAD-Rag2KO. Changes in amyloid burden, microglia characteristics and reactive astrocytes were evaluated using ELISA and confocal microscopy. NanoString Mouse AD multiplex gene expression analysis was applied to explore the impact of ex vivo expanded Tregs on the neuroinflammation transcriptome.Results: Elimination of mature B and T lymphocytes and natural killer cells in 5xFAD-Rag2KO mice was associated with upregulation of 95 inflammation genes and amplified number of reactive microglia within the dentate gyrus. Administration of ex vivo expanded Tregs reduced amyloid burden and reactive glial cells in the dentate gyrus and frontal cortex of 5xFAD-Rag2KO mice. Interrogation of inflammation gene expression documented down-regulation of pro-inflammatory cytokines (IL1A&B, IL6), complement cascade (C1qa, C1qb, C1qc, C4a/b), toll-like receptors (Tlr3, Tlr4 and Tlr7) and microglial activations markers (CD14, Tyrobp,Trem2) following Treg administration.Conclusions: Ex vivo expanded Tregs with amplified immunomodulatory function, suppressed neuroinflammation and alleviated AD pathology in vivo. Our results provide preclinical evidences for Treg cell therapy as a potential treatment strategy in AD.
- 30 September 2022
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 10 (1) , 1-13
Open AccessEx vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer’s disease
Background: Regulatory T cells (Tregs) play a neuroprotective role by suppressing microglia and macrophage-mediated inflammation and modulating adaptive immune reactions. We previously documented that Treg immunomodulatory mechanisms are compromised in Alzheimer’s disease (AD). Ex vivo expansion of Tregs restores and amplifies their immunosuppressive functions in vitro. A key question is whether adoptive transfer of ex vivo expanded human Tregs can suppress neuroinflammation and amyloid pathology in a preclinical mouse model.Methods: An immunodeficient mouse model of AD was generated by backcrossing the 5xFAD onto Rag2 knockout mice (5xFAD-Rag2KO). Human Tregs were expanded ex vivo for 24 days and administered to 5xFAD-Rag2KO. Changes in amyloid burden, microglia characteristics and reactive astrocytes were evaluated using ELISA and confocal microscopy. NanoString Mouse AD multiplex gene expression analysis was applied to explore the impact of ex vivo expanded Tregs on the neuroinflammation transcriptome.Results: Elimination of mature B and T lymphocytes and natural killer cells in 5xFAD-Rag2KO mice was associated with upregulation of 95 inflammation genes and amplified number of reactive microglia within the dentate gyrus. Administration of ex vivo expanded Tregs reduced amyloid burden and reactive glial cells in the dentate gyrus and frontal cortex of 5xFAD-Rag2KO mice. Interrogation of inflammation gene expression documented down-regulation of pro-inflammatory cytokines (IL1A&B, IL6), complement cascade (C1qa, C1qb, C1qc, C4a/b), toll-like receptors (Tlr3, Tlr4 and Tlr7) and microglial activations markers (CD14, Tyrobp,Trem2) following Treg administration.Conclusions: Ex vivo expanded Tregs with amplified immunomodulatory function, suppressed neuroinflammation and alleviated AD pathology in vivo. Our results provide preclinical evidences for Treg cell therapy as a potential treatment strategy in AD.
- Open Access
- 13 November 2018
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 13 (1) , 1-11
Functional alterations of myeloid cells during the course of Alzheimer’s disease
Neuroinflammation is a hallmark of neurodegenerative disease and a significant component of the pathology of Alzheimer’s disease (AD). Patients present with extensive microgliosis along with elevated pro-inflammatory signaling in the central nervous system and periphery. However, the role of peripheral myeloid cells in mediating and influencing AD pathogenesis remains unresolved. Peripheral myeloid cells were isolated from peripheral blood of patients with prodromal AD (n = 44), mild AD dementia (n = 25), moderate/severe AD dementia (n = 28), and age-matched controls (n = 54). Patients were evaluated in the clinic for AD severity and categorized using Clinical Dementia Rating (CDR) scale resulting in separation of patients into prodromal AD (CDR0.5) and advancing forms of AD dementia (mild-CDR1 and moderate/severe-CDR2/3). Separation of peripheral myeloid cells into mature monocytes or immature MDSCs permitted the delineation of population changes from flow cytometric analysis, RNA phenotype analysis, and functional studies using T cell suppression assays and monocyte suppression assays. During stages of AD dementia (CDR1 and 2/3) peripheral myeloid cells increase their pro-inflammatory gene expression while at early stages of disease (prodromal AD—CDR0.5) pro-inflammatory gene expression is decreased. MDSCs are increased in prodromal AD compared with controls (16.81% vs 9.53%) and have markedly increased suppressive functions: 42.4% suppression of activated monocyte-produced IL-6 and 78.16% suppression of T cell proliferation. In AD dementia, MDSC populations are reduced with decreased suppression of monocyte IL-6 (5.22%) and T cell proliferation (37.61%); the reduced suppression coincides with increased pro-inflammatory signaling in AD dementia monocytes. Peripheral monocyte gene expression is pro-inflammatory throughout the course of AD, except at the earliest, prodromal stages when pro-inflammatory gene expression is suppressed. This monocyte biphasic response is associated with increased numbers and suppressive functions of MDSCs during the early stages and decreased numbers and suppressive functions in later stages of disease. Prolonging the early protective suppression and reversing the later loss of suppressive activity may offer a novel therapeutic strategy.
- 13 November 2018
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 13 (1) , 1-11
Open AccessFunctional alterations of myeloid cells during the course of Alzheimer’s disease
Neuroinflammation is a hallmark of neurodegenerative disease and a significant component of the pathology of Alzheimer’s disease (AD). Patients present with extensive microgliosis along with elevated pro-inflammatory signaling in the central nervous system and periphery. However, the role of peripheral myeloid cells in mediating and influencing AD pathogenesis remains unresolved. Peripheral myeloid cells were isolated from peripheral blood of patients with prodromal AD (n = 44), mild AD dementia (n = 25), moderate/severe AD dementia (n = 28), and age-matched controls (n = 54). Patients were evaluated in the clinic for AD severity and categorized using Clinical Dementia Rating (CDR) scale resulting in separation of patients into prodromal AD (CDR0.5) and advancing forms of AD dementia (mild-CDR1 and moderate/severe-CDR2/3). Separation of peripheral myeloid cells into mature monocytes or immature MDSCs permitted the delineation of population changes from flow cytometric analysis, RNA phenotype analysis, and functional studies using T cell suppression assays and monocyte suppression assays. During stages of AD dementia (CDR1 and 2/3) peripheral myeloid cells increase their pro-inflammatory gene expression while at early stages of disease (prodromal AD—CDR0.5) pro-inflammatory gene expression is decreased. MDSCs are increased in prodromal AD compared with controls (16.81% vs 9.53%) and have markedly increased suppressive functions: 42.4% suppression of activated monocyte-produced IL-6 and 78.16% suppression of T cell proliferation. In AD dementia, MDSC populations are reduced with decreased suppression of monocyte IL-6 (5.22%) and T cell proliferation (37.61%); the reduced suppression coincides with increased pro-inflammatory signaling in AD dementia monocytes. Peripheral monocyte gene expression is pro-inflammatory throughout the course of AD, except at the earliest, prodromal stages when pro-inflammatory gene expression is suppressed. This monocyte biphasic response is associated with increased numbers and suppressive functions of MDSCs during the early stages and decreased numbers and suppressive functions in later stages of disease. Prolonging the early protective suppression and reversing the later loss of suppressive activity may offer a novel therapeutic strategy.